Pharmacokinetic Parameters for 111In-NLS-Trastuzumab Administered Intravenously or Intraperitoneally to Non–Tumor-Bearing BALB/c Mice
| Estimate | ||
|---|---|---|
| Pharmacokinetic parameter | Intravenously | Intraperitoneally |
| t1/2absorption (h) | NA | 1.93 |
| t1/2[α] (h) | 0.14 | NA |
| t1/2[β] (h) | 33.7 | 23.1 |
| V1 (mL) | 1.13 | NA |
| Vss (mL) | 1.69 | 1.19 |
| CLs (μL·h−1) | 34.7 | 37.9 |
| AUCintravenous (counts per min·h·μL−1) | 10.9 × 109 | 7.0 × 109 |
| Bioavailability (AUCintraperitoneal/AUCintravenous) | 0.7 | |
t1/2absorption = absorption half-life; NA = not applicable; t1/2[α] = distribution half-life; t1/2[β] = elimination half-life; V1 = volume of distribution of central compartment; CLs = systemic clearance; AUCintravenous = area under intravenous curve; AUCintraperitoneal = area under intraperitoneal curve.
Mice were administered 111In-NLS-tratuzumab via intravenous injection (9.25 MBq; 4 mg/kg) (n = 5).